Pentostatin and rituximab therapy for previously untreated patients with B‐cell chronic lymphocytic leukemia
Open Access
- 20 April 2010
- Vol. 116 (9), 2180-2187
- https://doi.org/10.1002/cncr.25028
Abstract
BACKGROUND: The combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) achieved an overall response (OR) rate >90%, with >40% complete responses (CRs) in patients with untreated chronic lymphocytic leukemia (CLL). METHODS: To evaluate whether the tolerability of this regimen could be enhanced without sacrificing efficacy, a phase 2 trial was conducted of P and R without C, using a higher P dose (4 mg/m2). Among the 33 patients enrolled, 82% were male, the median age was 65 years (9 patients were aged ≥70 years), and 64% were classified as having Rai stage III to IV disease. RESULTS: The OR rate was 76%, with 9 CRs (27%), 5 nodular partial responses, and 11 partial responses (PRs) reported. At the time of last follow‒up, 29 of 33 patients were still alive at a median follow‐up of 14 months (range, 1‐34.8 months). Four (12%) patients experienced grade 3 or higher hematologic toxicity, and 5 (15%) experienced grade 3 or higher nonhematologic toxicity. Comparison of this trial with the previous PCR trial demonstrated that patients treated with PCR had a higher OR rate (91% vs 76%) and CR rate (41% vs 27%) compared with patients treated with PR. The median treatment‐free survival for all accrued patients was notably longer in patients treated with PCR compared with PR (30 months vs 16 months). CONCLUSIONS: The findings of the current study suggest that increasing the dose of the purine nucleoside analogue does not eliminate the need for cyclophosphamide in chemoimmunotherapy for the treatment of CLL. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 23 references indexed in Scilit:
- Chemoimmunotherapy With Low-Dose Fludarabine and Cyclophosphamide and High Dose Rituximab in Previously Untreated Patients With Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2009
- Letter to the Editor: Community-Based Phase II Trial of PCR for CLL/SLL PatientsCancer Biotherapy & Radiopharmaceuticals, 2007
- The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemiaLeukemia, 2007
- Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemiaCancer, 2007
- Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997Journal of Clinical Oncology, 2007
- Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011Blood, 2005
- Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)Blood, 2002
- Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical courseLeukemia, 2002
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958